Conditions: Atrial Fibrillation New Onset Hemorrhage Prolonged QTc Interval Ventricular Tachycardia Medical Care; Complications, Late Effect of Complications
Keywords: Atrial Fibrillation New Onset Ranolazine CABG valve repair/replacement Cardiac Surgery
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 54
Healthy volunteers: no

Brief summary:
The aim of this study is to evaluate the prophylactic effects of Ranolazine on new onset atrial fibrillation in post-operative coronary artery bypass graft and valve surgery patient population at Staten Island University hospital.

Detailed description:
Atrial fibrillation (AF) is a common complication of cardiac surgery. It has been shown that the onset of AF increases in post-operative cardiac surgery population. The rate of AF after coronary artery bypass graft (CABG) procedure range from 10-65% and from 37-50% after valve surgery. Rates of new onset AF are lower for CABG compared to valve procedures. The pathophysiology of post-operative AF is not well elucidated. It has been postulated that pre-operative factors such as age, past medical history, operative and post-operative remodeling of the coronary system and hemodynamic pressure changes may contribute to post-operative AF.

Ranolazine is currently approved as an antianginal drug. The antianginal properties of the drug are due to inhibition of the late inward sodium current. Through the same mechanism it has been demonstrated in animal experiments and human studies that it can prevent atrial and ventricular arrhythmias.

Therefore it is important to prevent or minimize the incidence of new onset post-operative AF in post-surgical population.

Arms:
arm 1: The antianginal properties of the drug are due to inhibition of the late inward sodium current, demonstrated in animal experiments and human studies that it can prevent atrial and ventricular arrhythmias. arm 2: Company generated placebo, will be similar in size and color to Ranolazine; and administered two times a day (12 hour intervals)

Interventions: intervention 1: Ranolazine intervention 2: Placebo
Intervention descriptions: intervention 1: 1000mg, two times a day, 12 hour intervals intervention 2: two times a day, 12 hour intervals

Protocol document: